Price to earnings forward of Utah Medical Products, Inc. – NASDAQ:UTMD
This article provides financial data for Utah Medical Products, Inc. (NASDAQ: UTMD), specifically focusing on its forward price-to-earnings ratio. It indicates the stock's performance and financial metrics as of a specific period, noting if the market is closed or if there are no trades. The content highlights TradingView as the platform hosting this data.
Enterprise value to EBITDA forward of Utah Medical Products, Inc. – NASDAQ:UTMD
This article provides financial information for Utah Medical Products, Inc. (NASDAQ: UTMD), specifically focusing on its enterprise value to EBITDA forward metric. It highlights the company's stock information on the Nasdaq Stock Market and is presented within the TradingView platform's interface.
Enterprise value to EBIT forward of Utah Medical Products, Inc. – NASDAQ:UTMD
This article provides financial information for Utah Medical Products, Inc. (NASDAQ: UTMD), focusing on its enterprise value to EBIT forward. It indicates the latest financial health of the company as of the market close with no trades reported. The content is presented within the TradingView platform, which offers various financial tools and market data.
Price to sales forward of Utah Medical Products, Inc. – NASDAQ:UTMD
This article provides financial information for Utah Medical Products, Inc. (NASDAQ: UTMD), specifically focusing on its "Price to sales forward" metric. It appears to be a financial data snippet from TradingView, indicating the company's valuation based on future sales.
Price to book forward of Utah Medical Products, Inc. – NASDAQ:UTMD
The article title indicates that it likely discusses the "Price to book forward" metric for Utah Medical Products, Inc. (NASDAQ:UTMD). However, the body of the article appears to be primarily composed of navigation links and website boilerplate, rather than specific financial analysis. The critical financial data for UTMD regarding this metric is not present within the provided content.
Form 4 Utah Medical Products Inc For: 1 July By Investing.com
This article from Investing.com reports on a Form 4 filing for Utah Medical Products Inc (UTMD) as of July 1st. Form 4s disclose transactions made by company insiders. The article indicates a 3.04% change in UTMD's stock and provides various financial market data and popular news headlines alongside the main announcement.
UTAH MEDICAL PRODUCTS (UTMD) director reports 150-share bona fide stock gift
UTAH MEDICAL PRODUCTS INC (UTMD) director Paul O. Richins reported an indirect bona fide gift of 150 shares of Common Stock, valued at $73.07 per share. Following this transaction, Richins's indirect holdings total 20,765 shares, held across various accounts including IRAs and the Richins Family Trust. This transaction is classified as a non-market gift transfer rather than a sale.
Form 4 Utah Medical Products Inc For: 1 July By Investing.com
This article from Investing.com reports on a Form 4 filing for Utah Medical Products Inc. on July 1st. The filing pertains to insider transactions, with the article providing the basic headline and indicating that more details might be available within the financial markets platform.
Responsive Playbooks and the UTMD Inflection
Utah Medical Products Inc. (NASDAQ: UTMD) is experiencing a breakout with strong near-term sentiment and compelling upside potential. AI-driven models provide tailored trading strategies including position trading, momentum breakout, and risk hedging, alongside multi-timeframe signal analysis. The stock shows no resistance levels above its current price, suggesting further gains.
Utah Medical Products Inc (UTMD) Institutional Confidence
Utah Medical Products Inc (UTMD) has an institutional shareholding score of 7.00, placing it 79th out of 204 in the Healthcare Equipment & Supplies industry. Institutional shareholding proportion recently increased by 8.51% quarter-over-quarter to 76.75%. Bill Nygren | OAKMX is the largest institutional shareholder, holding 14.11% of outstanding shares.
Utah Medical Products Inc (UTMD) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article details the dividend history and stock split information for Utah Medical Products Inc (UTMD). It provides a comprehensive table of past and upcoming dividend payments, including record dates, payment dates, and ex-dividend dates, along with the gross cash dividend amount. The company has distributed a total of $23.17 million in dividends over the past five years, with no stock splits recorded.
Utah Medical Products Inc (UTMD) Valuation: PE, PB & Fair Value Analysis
The article provides a valuation analysis of Utah Medical Products Inc (UTMD), stating its current valuation score is 7.89, ranking 125 out of 203 in the Healthcare Equipment & Supplies industry. It highlights the company's current P/E ratio of 19.82, noting it's below a recent high but above a recent low. The article also mentions that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Utah Medical Products Inc (UTMD) Shareholder Structure: Major Shareholders & Institutional Holdings
The article details the shareholder structure of Utah Medical Products Inc (UTMD), listing its major institutional and individual holders, updated as of specific dates in 2025 and 2026. It presents institutional holding trends over several quarters and lists ETFs that include UTMD, providing a comprehensive overview of its ownership. Key shareholders include Brandes Investment Partners, L.P., Dimensional Fund Advisors, L.P., and Renaissance Technologies LLC.
Utah Medical Products Stock - Thursday chart snapshot and volatility check
Utah Medical Products (UTMD) stock traded in a relatively tight range on Thursday, fluctuating between $65 and $67 with muted short-term volatility. The company, which specializes in medical devices for obstetrics, gynecology, and neonatal intensive care, saw its shares trade around $65.70 on the Nasdaq. The article notes the absence of major market catalysts and highlights key financial details, including its $209.57 million market capitalization.
Utah Medical Products Inc (UTMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Utah Medical Products Inc (UTMD), categorizing its revenue by business segment and geographical region. The company's main business segments are Gynecology/Electrosurgery/Urology, Neonatal, Blood Pressure Monitoring and Accessories, and Obstetrics, with the majority of revenue coming from the United States, followed by Europe and other regions. Financial figures are presented for various fiscal years and quarters, with the most recent data updated on April 6.
Utah Medical Products Inc (UTMD) Risk Assessment: Volatility, Financial Risk & Investment Risk
|
Utah Medical Products Inc (UTMD) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Utah Medical Products Inc (UTMD), detailing its current price momentum score, support and resistance levels, and indicator readings. It shows that UTMD is currently trading in a range-bound manner, with indicators mostly signaling "Sell," particularly for short-term moving averages. The analysis also includes FAQs explaining technical ratings and moving averages, and offers a summary based on these technical metrics.
The Technical Signals Behind (UTMD) That Institutions Follow
This article from Stock Traders Daily discusses the technical signals for Utah Medical Products Inc. (NASDAQ: UTMD), highlighting strong sentiment across all horizons and an exceptional 24.6:1 risk-reward setup. It outlines three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, along with a multi-timeframe signal analysis. The report indicates strong signals for Near-term, Mid-term, and Long-term horizons, providing crucial support and resistance levels.
The Technical Signals Behind (UTMD) That Institutions Follow
This article from Stock Traders Daily analyzes Utah Medical Products Inc. (NASDAQ: UTMD), highlighting strong sentiment and a mid-channel oscillation pattern. It presents institutional trading strategies, including a position trading strategy, momentum breakout strategy, and risk-hedging strategy, alongside multi-timeframe signal analysis. The report identifies an exceptional 24.6:1 risk-reward setup targeting a 7.1% gain versus a 0.3% risk.
Utah Medical Products, Inc. (UTMD) Leadership & Management Team Analysis
This article provides an analysis of Utah Medical Products, Inc. (UTMD)'s leadership, management, and recent company updates. It highlights key personnel information, board appointments, insider transactions, and dividend announcements, alongside earnings reports and analytical perspectives on the company's financial performance and risks. The content also touches on UTMD's market valuation, profitability, and legal challenges.
Brandes Investment Partners holds 14.12% of Utah Medical Products (NASDAQ: UTMD)
Brandes Investment Partners has filed an amended Schedule 13G, disclosing a beneficial ownership of 449,680 shares in Utah Medical Products (UTMD), which represents 14.12% of the company's class. The filing indicates that Brandes holds shared voting power over 412,007 of these shares, with the amendment signed by Glenn Carlson as Executive Director. This is a routine disclosure for large passive investors, signaling no immediate intent to influence control but providing transparency on significant holdings.
Utah Medical Products (NASDAQ: UTMD) Q1 2026 sales and profit decline
Utah Medical Products (UTMD) reported a decline in its Q1 2026 sales and profit compared to a strong prior year. Net sales decreased by 10.2% to $8,722k, primarily due to the loss of a major China distributor and an OEM customer, leading to a 14.4% drop in net income to $2,604k. Despite the revenue and earnings contraction, the company maintained strong gross margins and a robust balance sheet with significant cash reserves and no debt, continuing its share repurchase and dividend policy.
Utah Medical Products (Nasdaq:UTMD) - Stock Analysis
This report provides a stock analysis for Utah Medical Products (Nasdaq:UTMD), highlighting its current valuation, dividend performance, and recent financial updates. The company is trading 48.6% below its estimated fair value and offers a reliable dividend yield of 1.9%, well-covered by earnings and cash flows, despite a decline in earnings over the past five years. Recent news includes dividend declarations, annual general meetings, and quarterly earnings reports detailing revenue and EPS changes.
Number of shareholders of Utah Medical Products, Inc. – NASDAQ:UTMD
This article from TradingView provides information on Utah Medical Products, Inc. (UTMD) with a focus on financial data, specifically the number of shareholders. It appears to be an overview page for UTMD's financial metrics. The specific shareholder numbers are not directly in the provided text, but the structure indicates this section would contain such details.
Utah Medical Products To Go Ex-Dividend On June 17th, 2026 With 0.31 USD Dividend Per Share
Utah Medical Products announced it will go ex-dividend on June 17th, 2026, offering a dividend of $0.31 per share. Investors must own shares before this date to be eligible for the payment. This information is crucial for shareholders and potential investors tracking dividend payouts.
Utah Medical Products, Inc. announces Quarterly dividend, payable on July 03, 2026
Utah Medical Products, Inc. (UTMD) has announced a quarterly dividend of $0.3100 per share, payable on July 3, 2026. The ex-dividend date and record date for this payment are both set for June 17, 2026. The company specializes in producing medical devices for critical care areas and women's health.
Utah Medical Products raises quarterly dividend 1.6%
Utah Medical Products Inc. (NASDAQ:UTMD) has announced a 1.6% increase in its quarterly cash dividend to $0.31 per share. This marks the third consecutive year of dividend increases for the company, maintaining dividend payments for 23 consecutive years. The dividend will be paid on July 3, 2026, to shareholders of record by June 17, 2026, with the company currently trading at a P/E ratio of 19 and appearing undervalued according to InvestingPro’s Fair Value analysis.
Utah Medical Products, Inc. Announces Quarterly Dividend
Utah Medical Products, Inc. (Nasdaq:UTMD) announced that its Board of Directors approved a quarterly cash dividend of thirty-one cents per share of common stock. This dividend is payable on July 3, 2026, to stockholders of record as of June 17, 2026. This represents a 1.6% increase over the dividend declared in the same quarter of the prior year.
Utah Medical raises quarterly dividend to $0.31 | UTMD Stock News
Utah Medical Products (NASDAQ: UTMD) has announced a quarterly cash dividend of $0.31 per share, payable on July 3, 2026, to shareholders of record as of June 17, 2026. This represents a 1.6% increase compared to the dividend declared in the same quarter last year. The company specializes in developing and marketing disposable and reusable medical devices for maternal and neonatal care globally.
Utah Medical Products raises quarterly dividend 1.6%
Utah Medical Products Inc. (NASDAQ:UTMD) has announced a 1.6% increase in its quarterly cash dividend to $0.31 per share of common stock. This marks the third consecutive year of dividend increases for the company, which has maintained dividend payments for 23 years. The dividend will be paid on July 3, 2026, to stockholders of record by June 17, 2026.
Trading the Move, Not the Narrative: (UTMD) Edition
This article analyzes Utah Medical Products Inc. (NASDAQ: UTMD), highlighting weak near and mid-term sentiment but a strong long-term outlook. It identifies resistance testing and suggests an exceptional short setup due to a favorable risk-reward ratio. The report details three AI-generated trading strategies—position, momentum breakout, and risk hedging—tailored to different risk profiles.
Utah Medical Products, Inc. Declares Quarterly Dividend of $0.31 (NASDAQ:UTMD)
Utah Medical Products, Inc. (NASDAQ:UTMD) announced a quarterly dividend of $0.31 per share, to be paid on July 3rd to shareholders of record by June 17th. The dividend represents an annualized yield of 1.9%. The medical instruments supplier recently reported quarterly EPS of $0.82 on $8.72 million in revenue and has a market capitalization of $202.3 million.
Utah Medical (UTMD) investors approve directors, auditor and executive pay
Utah Medical Products, Inc. (UTMD) stockholders approved the election of Ernst G. Hoyer and James H. Beeson as directors, ratified Haynie & Co. as their independent public accounting firm for 2026, and, on an advisory basis, approved the compensation for executive officers at their annual meeting on May 1, 2026. The company intends to continue holding annual advisory votes on executive compensation. These decisions were formally reported in an 8-K filing.
Utah Medical Products (NASDAQ:UTMD) Shares Pass Above 200-Day Moving Average - Time to Sell?
Utah Medical Products (NASDAQ:UTMD) has seen its stock price cross above its 200-day moving average, trading as high as $65.68. The company reported quarterly earnings of $0.82 per share on revenue of $8.72 million and recently declared a quarterly dividend of $0.31 per share. Analysts generally rate the stock as "Hold," with institutional investors showing varied activity in their holdings.
Utah Medical's Q1 Earnings Fall Y/Y Due to Elevated Litigation Costs
Utah Medical Products (UTMD) reported an 11% decline in Q1 2026 earnings per share and a 10.2% drop in net sales year-over-year, underperforming the S&P 500. The decline was primarily attributed to the loss of sales from a former Chinese distributor and an OEM customer, alongside higher litigation costs and elevated operating expenses. Despite these challenges, the company maintained a strong balance sheet and indicated that full-year results are expected to align with previous projections.
Utah Medical's Q1 Earnings Fall Y/Y Due to Elevated Litigation Costs
Utah Medical Products (UTMD) reported a decline in Q1 2026 earnings per share and net sales, primarily due to elevated litigation costs and the absence of sales to a former Chinese distributor. Despite a robust balance sheet with no debt, increased cash, and an improved gross profit margin, operating and net income margins fell. The company expects full-year results to align with prior projections, anticipating some cost normalization later in the year.
Utah Medical Products (UTMD) Margin Compression Challenges Bullish Valuation Narratives Heading Into Q1 2026
Utah Medical Products (UTMD) is facing margin compression, with its net profit margin decreasing from 33.9% to 29.3% over the last year, alongside a 1.7% annual earnings decline over five years. Despite a seemingly attractive DCF fair value of US$116.24 compared to its current price of US$67.17, investors are challenged by slowing revenue growth and pressure on profitability. The company's 19x P/E ratio is above its peer average but below the industry, suggesting a cautious market sentiment due to its recent financial performance.
Utah Medical Products (UTMD) Q1 2026 Earnings: EPS $0.818, Revenue $8.72M -- Is It 12.5% Overvalued?
Utah Medical Products (UTMD) reported Q1 2026 earnings with diluted EPS of $0.818 and net sales of $8.72 million, marking a 10.2% year-over-year decline attributed to lost distributor and OEM volumes. Despite the sales drop, the company achieved gross margin expansion to 60.6% and maintains a strong, debt-free balance sheet with $87.41 million in cash, supported by ongoing share repurchases and dividends. GuruFocus values UTMD as 12.5% overvalued with a GF Score of 81/100, citing strong financial health and profitability but modest growth prospects.
Utah Medical Products (UTMD) Q1 2026 Earnings: EPS $0.818, Revenue $8.72M -- Is It 12.5% Overvalued?
Utah Medical Products (UTMD) reported a decline in Q1 2026 net sales and net income, largely due to the absence of sales to former distributors and OEM customers, which aligned with internal expectations. Despite the sales decline, the company achieved gross margin expansion and maintained a strong, debt-free balance sheet with significant cash and investments. UTMD's stock is currently considered 12.5% overvalued by GuruFocus, but its strong financial health and profitability indicators suggest a resilient company.
Utah Medical: Q1 Earnings Snapshot
Utah Medical Products Inc. (UTMD) reported earnings of $2.6 million, or 82 cents per share, in its first quarter. The medical device maker also announced revenue of $8.7 million for the period. This financial summary was generated using data from Zacks Investment Research.
Utah Medical Products (NASDAQ:UTMD) Issues Quarterly Earnings Results
Utah Medical Products (NASDAQ:UTMD) reported quarterly earnings per share of $0.82, with a net margin of 29.3% and a return on equity of 9.56%. The company also declared a quarterly dividend of $0.31 per share, leading to an annualized dividend of $1.24 and a yield of 1.8%. The stock traded at $70.69, reflecting a market cap of approximately $225 million and a P/E ratio of 20.31.
Double-digit revenue drop but strong margins at Utah Medical (Nasdaq: UTMD)
Utah Medical Products (UTMD) reported a significant decline in Q1 2026 revenue and net income, with net sales dropping 10.2% to $8.7 million and net income falling 14.4% to $2.6 million. This downturn was primarily attributed to the loss of key distribution and OEM relationships, specifically with a former China distributor and PendoTECH. Despite the revenue challenges, the company maintained strong profitability, with gross margin improving to 60.6%, and sustained a robust, debt-free balance sheet with increased cash and investments.
Utah Medical: Q1 Earnings Snapshot
Utah Medical Products Inc. (UTMD) announced its first-quarter earnings, reporting $2.6 million in net income. The medical device manufacturer posted a profit of 82 cents per share and generated $8.7 million in revenue for the quarter.
Utah Medical: Q1 Earnings Snapshot
Utah Medical Products Inc. (UTMD) reported its first-quarter earnings, detailing a profit of $2.6 million. The medical device maker achieved 82 cents profit per share and generated $8.7 million in revenue for the period.
Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2026
Utah Medical Products, Inc. (Nasdaq:UTMD) reported financial results for the first quarter of 2026, which were consistent with prior projections despite some declines compared to 1Q 2025. Key figures show a decrease in revenues, gross profit, operating income, net income, and EPS, largely attributed to the absence of sales to a former China distributor and an OEM customer. The company's balance sheet remains strong, with increased cash and investments, and continued share repurchases and dividend payments.
Utah Medical lost China sales in Q1, but gross margin rose to 60.6%
Utah Medical Products (UTMD) reported a decline in consolidated sales by 10.2% and EPS by 11.0% in Q1 2026, primarily due to lost sales to a former China distributor and PendoTECH. Despite lower revenues, the company's gross profit margin improved to 60.6%, and cash equivalents increased by $4.1 million year-over-year. The report highlights the company's mixed performance with earnings pressure offset by balance sheet strength and continued shareholder returns through dividends and share repurchases.
Utah Medical: Q1 Earnings Snapshot
Utah Medical Products Inc. (UTMD) reported first-quarter earnings of $2.6 million, translating to 82 cents per share. The medical device manufacturer also announced a revenue of $8.7 million for the period. This financial snapshot was generated by Automated Insights using data from Zacks Investment Research.
Utah Medical Products, Inc. Hits New 52-Week High at $69.01
Utah Medical Products, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week high of $69.01, a significant increase from its 52-week low of $51.26. The company boasts a market capitalization of USD 205 million, a P/E ratio of 18.00, and a remarkable dividend yield of 108.47%, despite its one-year performance of 1.94% lagging behind the S&P 500. With a debt-to-equity ratio of -0.71 and a return on equity of 9.46%, the company demonstrates a solid financial position.
Utah Medical Products, Inc. Experiences Revision in Stock Evaluation Amid Strong Financial Metrics
Utah Medical Products, Inc. has adjusted its stock valuation, now featuring a P/E ratio of 18 and an impressive dividend yield of 108.47%. The company has demonstrated strong financial performance, with a year-to-date return of 22.94%, significantly outperforming the S&P 500. These strong metrics and favorable comparisons to competitors highlight its competitive edge in the Pharmaceuticals & Biotechnology sector.
Utah Medical Products, Inc. Hits New 52-Week High at $69.55
Utah Medical Products, Inc. (UTMD) has reached a new 52-week high of $69.55, indicating strong performance within the pharmaceuticals and biotechnology sector. The microcap company, with a market capitalization of $205 million, has shown a 3.05% increase over the past year and boasts an impressive 108.47% dividend yield, alongside solid financial metrics like an 18.00 P/E ratio, 9.46% return on equity, and a 1.72 price-to-book ratio.
